Clinical trial NCT05540288: NAlmefene Versus Placebo in Addition to Treatment as Usual on Craving in Behavioural Addictions
Official title: NAlmefene Versus Placebo in Addition to Treatment as Usual on Craving in Behavioural Addictions
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Behavioural Addiction
Keywords: Nalmefene
Craving
Behavioural addiction
Gambling disorder
Food addiction
Sexual addiction
Lead sponsor: Nantes University Hospital
Sponsor class: OTHER
First posted: 2022-09-14
Enrollment: 266
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Behavioural addictions (BAs) \[gambling disorder (GD), food addiction (FA), sexual addiction (SA)\] may lead to disastrous consequences. They are often associated with other addictive or psychiatric disorders, and high rates of suicide attempts. Epidemiological studies report prevalence reaching 2.7% for GD, 5% for SA, and up to 7.9% for FA.

Many similarities have been highlighted between BAs, as well as with substance use disorders. One core clinical similarity between those disorders is craving (uncontrollable urge to engage in rewarding behaviours), which has been consistently associated with diminished control over the behaviour and relapse.

At present, no pharmacological treatment has been approved for BAs, but several medications have been tested. Among them, two opioid receptor antagonists - naltrexone and nalmefene - appear the most promising. By decreasing dopamine neurotransmission in the reward circuitry, they reduce both excitement for rewarding behaviours and craving.

Compared to naltrexone, nalmefene seems to have a better safety. To date, no study investigated the efficacy of nalmefene as a pan-addiction treatment for BAs. Two clinical trials have demonstrated its efficacy for the treatment of GD, but no clinical trial was conducted for FA and SA.

The investigators hypothesise that nalmefene (36 mg/d), compared to a placebo, can have a therapeutic effect as an add-on to usual treatment for decreasing craving in several BAs.


Eligibility criteria: Pre-inclusion Criteria:

* Males and females ≥ 18 years old
* Patient already in care or newly initiating care in Addictology departments for a beharioural addiction, diagnosed with current:

  * Gambling disorder \[NORC DSM Screen for Gambling Problems (NODS), revised for DSM-5\]
  * Food addiction \[Yale Food Addiction Scale (YFAS), revised for DSM-5\]
  * Or Sexual addiction \[interview adapted from the NODS to explore the diagnostic criteria proposed by Carnes et al. (2012): NODS-SA\]
* Able to regularly assess and report their craving episodes on a weekly diary
* Who provide their written informed consent
* Affiliated with French social security system or beneficiary from such system

Inclusion Criteria:

* Having presented at least one episode of craving with an intensity ≥ 4/10 at the NRS during the week prior to inclusion

Women must meet one of the following criteria at the time of inclusion:

* use adequate contraceptive measures as recommended by the CTFG (Recommendations related to contraception and pregnancy testing in clinical trials v1.1), and have a negative pregnancy test (urine test) prior to receiving the first dose of study drug;
* or be post-menopausal (over 50 years of age with amenorrhea for at least 12 months after discontinuation of all exogenous hormonal therapy)
* or (if under 50 years of age) have been amenorrheic for at least 12 months after discontinuation of exogenous hormonal therapy and with luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels corresponding to post-menopausal levels
* or have undergone irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy (this operation must be documented).

Exclusion Criteria:

* Being currently treated by another anti-craving drug that have been already tested for craving reduction in BAs (naltrexone, acamprosate, baclofène, topiramate, bupropion, N-acetyl-cystéine, disulfiram, etc.);
* Presenting a contraindication for the use of nalmefene (listed in the SmPC):

  * Known hypersensitivity to the active substance or to any of the excipients. In particular, intolerance to galactose or deficiency in Lapp lactase or glucose-galactose malabsorption (rare hereditary diseases);
  * Treatment by opioid agonists (full or partial) (opioid pain relievers, opioid substitution drugs);
  * Recent history of opioid dependence or current opioid dependence;
  * Current symptoms of the acute opioid withdrawal syndrome;
  * Suspected recent consumption of opioid (necessity to consider the half-life);
  * Severe hepatic impairment (Child-Pugh stage B or C);
  * Severe renal impairment (estimated glomerular filtration rate \[TFGe\] \<30 mL/min/1.73 m2);
  * History of recent acute alcohol withdrawal syndrome (including hallucinations, convulsions and delirium tremens).
* Predictable opioid treatment during the study period;
* Unstable psychiatric disorders (meaning disorders for which the treatment was modified since less than a month (corresponding to the instauration of a new treatment, or the increase in dosage of a treatment already being taken)), including severe risk of suicide (i.e. necessity to engage specific medication or hospitalization; psychotropic medication engaged since less than 1 month; absence of improvement after one month of medication) (because nalmefene has not been studied in patients with unstable psychiatric disorders). Patients with a food addiction diagnosed with eating disorders marked by the presence of binge eating can be included;
* Anorexia nervosa-restricting type (because food addiction concept is poorly established among patients with AN-R, who do not have binge eating episodes induced by craving);
* Extreme leanness (body mass index \< 16.5) (because loss of appetite and/or weight loss are frequent adverse effects of nalmefene);
* Current treatment with potent inhibitor drugs of the UGT2B7 (UDP-Glucuronosyltransferase-2B7); for example: diclofenac, fluconazole, medroxyprogesterone acetate, meclofenamic acid;
* Current treatment with UGT inducing drugs; for example: dexamethasone, phenobarbital, rifampicin, omeprazole;
* Inability to indicate the time of day of the most intense craving episode (because this information will determine the time of day the treatment should be taken);
* Pregnancy (attested by a pregnancy urinary test for women of childbearing age) or breastfeeding woman;
* Trusteeship;
* Major cognitive impairment;
* Not fluent in French;
* Participation to another interventional study during the last month or expected participation to another interventional study during participation to the NABAB study.

Primary outcomes:
measure: Variation of averaged intensity of craving episodes between start and end of treatment.
timeFrame: 5 weeks
Secondary outcomes:
measure: Variation of averaged weekly frequency (number of episodes) of craving episodes between start and end of treatment.
timeFrame: 5 weeks
measure: Variation of averaged weekly duration (cumulative duration of all episodes) of craving episodes between start and end of treatment.
timeFrame: 5 weeks
measure: Variation of averaged weekly intensity, frequency and duration of craving episodes between start of treatment and 4 weeks after the end of treatment.
timeFrame: 9 weeks (5 weeks of treatment +4 weeks of follow up after treatment)
measure: Variation of averaged weekly frequency of the BA episodes: (i) between start and end of treatment and (ii) between start of treatment and 4 weeks after the end of treatment.
timeFrame: 9 weeks
measure: Variation of averaged weekly duration of the BA episodes: (i) between start and end of treatment and (ii) between start of treatment and 4 weeks after the end of treatment.
timeFrame: 9 weeks
measure: Variation of averaged weekly intensity of the BA episodes: (i) between start and end of treatment and (ii) between start of treatment and 4 weeks after the end of treatment.
timeFrame: 9 weeks
measure: Overall clinical improvement, assessed though the Clinical Global Impression - Improvement (CGI-I) scale.
timeFrame: 9 weeks
measure: Overall clinical improvement, assessed though the GGI - Efficacy Index (CGI-EI).
timeFrame: 9 weeks
measure: Variation of averaged weekly use of psychoactive substances (including nicotine) and daily life behaviors of interest (gambling, sex, food) between start of treatment and 4 weeks after the end of treatment
timeFrame: 9 weeks
measure: Number, type and severity of self-reported adverse side effects, during either weeks of treatment at a dosage of 18 mg/d or 36 mg/d.
timeFrame: 9 weeks
measure: Mutation(s) associated with non-response to nalmefene treatment
timeFrame: 9 weeks
measure: Sociodemographic, medical and clinical data, especially psychiatric and addictive co-morbidities assessed with the Mini International Neuropsychiatric Interview - Simplified (MINI-S) and the age of the BA
timeFrame: 1 week
Other outcomes:
Locations:
city: Besançon
country: France
facility: CHU de Besançon
city: Bordeaux
country: France
facility: CHU de Bordeaux
city: Brest
country: France
facility: CHRU de Brest
city: Clermont-Ferrand
country: France
facility: CHU de Clermont Ferrand
city: Dijon
country: France
facility: CHU de Dijon
city: La Rochelle
country: France
facility: CH de La Rochelle
city: Lyon
country: France
facility: Hospices Civils de Lyon
city: Montpellier
country: France
facility: CHU de Montpellier
city: Nantes
country: France
facility: CHU de Nantes
city: Nîmes
country: France
facility: CHU de Nîmes
city: Strasbourg
country: France
facility: Hôpitaux Universitaires de Strasbourg
city: Tours
country: France
facility: CHRU de Tours
city: Villejuif
country: France
facility: Hôpital Paul Brousse
Study officials:
affiliation: Nantes University Hospital
name: Marie GRALL-BRONNEC
role: PRINCIPAL_INVESTIGATOR
References: